Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Difference in safety and humoral response to mRNA SARS-CoV-2 vaccines in patients with autoimmune neurological disorders: the ANCOVAX study.
Giannoccaro MP, Vacchiano V, Leone M, Camilli F, Zenesini C, Panzera I, Balboni A, Tappatà M, Borghi A, Salvi F, Lugaresi A, Rinaldi R, Di Felice G, Lodi V, Lazzarotto T, Liguori R; ANCOVAX study group. Giannoccaro MP, et al. Among authors: lugaresi a. J Neurol. 2022 Aug;269(8):4000-4012. doi: 10.1007/s00415-022-11142-7. Epub 2022 May 3. J Neurol. 2022. PMID: 35503375 Free PMC article.
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. Kalincik T, et al. Among authors: lugaresi a. Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11. Lancet Neurol. 2017. PMID: 28209331 Free article.
Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
Lizak N, Malpas CB, Sharmin S, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Lugaresi A, Duquette P, Girard M, Prat A, Larochelle C, Trojano M, Grand'Maison F, Grammond P, Sola P, Ferraro D, Hupperts R, Bergamaschi R, Boz C, Van Pesch V, Spitaleri D, Terzi M, Kalincik T; MSBase Study Group. Lizak N, et al. Among authors: lugaresi a. JAMA Neurol. 2020 Nov 1;77(11):1398-1407. doi: 10.1001/jamaneurol.2020.2453. JAMA Neurol. 2020. PMID: 32716480 Free PMC article.
Frequency and characteristics of dysautonomic symptoms in multiple sclerosis: a cross-sectional double-center study with the validated Italian version of the Composite Autonomic Symptom Score-31.
Foschi M, Giannini G, Merli E, Mancinelli L, Zenesini C, Viti B, Guaraldi P, Cortelli P, Lugaresi A. Foschi M, et al. Among authors: lugaresi a. Neurol Sci. 2021 Apr;42(4):1395-1403. doi: 10.1007/s10072-020-04620-1. Epub 2020 Aug 10. Neurol Sci. 2021. PMID: 32776288 Free PMC article.
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy.
Baldin E, Zenesini C, Antonazzo IC, Bartolomei I, Caniatti L, Costa M, Curti E, Ferraro D, Foschi M, Granella F, Guareschi A, Immovilli P, Lugaresi A, Malagù S, Mancinelli L, Montepietra S, Mussuto V, Neri W, Pasquinelli M, Pellegrino L, Pesci I, Poluzzi E, Pugliatti M, Ravasio A, Riise T, Salvi F, Santangelo M, Sireci F, Sola P, Strumia S, Tsantes E, Vignatelli L, Vitetta F, Viti B, D'Alessandro R; AS_MS_Risk Group. Baldin E, et al. Among authors: lugaresi a. Neuroepidemiology. 2021;55(3):224-231. doi: 10.1159/000515682. Epub 2021 May 7. Neuroepidemiology. 2021. PMID: 33965951
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
Chisari CG, Comi G, Filippi M, Paolicelli D, Iaffaldano P, Zaffaroni M, Brescia Morra V, Cocco E, Marfia GA, Grimaldi LM, Inglese M, Bonavita S, Lugaresi A, Salemi G, De Luca G, Cottone S, Conte A, Sola P, Aguglia U, Maniscalco GT, Gasperini C, Ferrò MT, Pesci I, Amato MP, Rovaris M, Solaro C, Lus G, Maimone D, Bergamaschi R, Granella F, Di Sapio A, Bertolotto A, Totaro R, Vianello M, Cavalla P, Bellantonio P, Lepore V, Patti F; Italian MS Register Study Group.. Chisari CG, et al. Among authors: lugaresi a. J Neurol. 2022 Feb;269(2):933-944. doi: 10.1007/s00415-021-10676-6. Epub 2021 Jun 28. J Neurol. 2022. PMID: 34181077
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P, Lucisano G, Manni A, Paolicelli D, Patti F, Capobianco M, Brescia Morra V, Sola P, Pesci I, Lus G, De Luca G, Lugaresi A, Cavalla P, Montepietra S, Maniscalco GT, Granella F, Ragonese P, Vianello M, Brambilla L, Totaro R, Toscano S, Malucchi S, Petracca M, Moiola L, Ferraro D, Lepore V, Mosconi P, Ponzio M, Tedeschi G, Comi G, Battaglia MA, Filippi M, Amato MP, Trojano M; Italian MS Register. Iaffaldano P, et al. Among authors: lugaresi a. Neurol Neuroimmunol Neuroinflamm. 2022 Jan 19;9(2):e1141. doi: 10.1212/NXI.0000000000001141. Print 2022 Mar. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 35046084 Free PMC article.
282 results